Thymulin levels in mice and humans decrease with age as levels of chronic myeloid inflammation
increase.
Compared to aged mice, levels of pro inflammatory cytokines IL-1a, IL-1b, IL-6 and TNFa and were decreased in bone marrow chimeric mice. This was also observed in old mice treated with Thymulin peptide. A similar effect was observed in human PBMC treated with thymulin peptide in vitro. Anti-Cancer immune response from PD-1 intervention in Tumor bearing aged mice was significantly improved when mice were supplemented with thymulin peptide.
“Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy”, Fumito Ito, Hisashi Kanemaru, et al. (21 July 2026) Nature Communications 17: 6534. PMID: 42481458 PMCID: PMC13389034 DOI: 10.1038/s41467-026-75383-0
Relevant Ancell Products